Abbott Laboratories Inc.

Abbott Laboratories Inc., Abbott Point Of Care Division, a for-profit manufacturer of medical devices and diagnostic equipment headquartered in North Chicago, Illinois, operates exclusively as a prime contractor supplying point-of-care diagnostic consumables, cartridges, test reagents, and whole blood glucose monitoring equipment to federal health agencies. The vendor competes on full-and-open contracts with no set-aside posture and holds no significant secondary SBA designations.

Abbott's federal footprint concentrates overwhelmingly with the Defense Logistics Agency Medical Supply Chain, which accounts for 40,439 awards (97% of award count) with $304.1 million in combined potential value, representing roughly 17% of the $1.82 billion total potential value across all 42,281 prime awards. The remaining customer base splits across Department of Veterans Affairs VISN networks — notably VISN 12 with 81 awards but $1.06 billion in potential value, VISN 6 with 213 awards and $32.9 million, VISN 8 with 167 awards and $31.4 million, and VISN 10 with 242 awards and $8.4 million. The divergence between count-heavy DLA rankings and dollar-heavy VISN 12 rankings signals that Abbott's VISN work anchors larger-dollar, longer-duration arrangements while DLA business fragments across hundreds of small delivery orders for cartridges and diagnostic supplies. Abbott also serves the Defense Health Agency (40 awards, $62.6 million) and the Department of the Army Medical Command (54 awards, $48.7 million).

Recent representative work includes a $2.764 billion Blanket Purchase Agreement awarded by VISN 8 on July 1, 2026, for whole blood glucose monitoring equipment and services across seven Florida and Puerto Rico VA facilities through June 30, 2031; a $36,505.05 delivery order from VISN 10 in June 2026 for blood analyzers; a $412,400 purchase order from VISN 20 in May 2026 for on-site maintenance and repair of Abbott EnSite cardiac mapping systems through April 2029; a $102,140.36 BPA call from VISN 8 for whole blood glucose monitoring in July 2026; and dozens of sub-million-dollar DLA delivery orders issued between April and July 2026 for i-STAT cartridges, CHEM 8 cartridges, metabolic panels, FreeStyle glucose test strips, and Abbott FreeStyle Libre 3 sensors. Work is performed primarily at Abbott's North Chicago headquarters, with some performance at customer sites in Alameda, California (Federal Correctional Complex Butner), Seattle, Washington (VISN 20), Portland, Oregon (VA Portland Healthcare System), and West Palm Beach, Florida (VISN 8 West Palm Beach VAMC).

Abbott operates under five primary indefinite delivery vehicles placed by DLA: Indefinite Delivery Contract SPE2DH14D0013 (15,835 task orders, $28 million), SPE2DH19D0020 (15,667 task orders, $27 million), SPE2DH25D0001 (4,017 task orders, $8.3 million), SPE2D019D0008 (2,877 task orders, $3.2 million), and SPM2D011D0002 (2,031 task orders, $3.5 million). Abbott also holds BPA positions including the VISN 8 whole blood glucose monitoring BPA, the GSA Multiple Award Schedule for clinical laboratory analyzers and diagnostic devices, and the GSA Schedule for In-Vitro Diagnostics, Reagents, and Tests (FSS-65-VII). The vendor's catalog spans NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) as the dominant classification, with secondary work under NAICS 423450 (Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers), covering 35,536 awards. PSC-level focus centers on Hospital Furniture, Equipment, Utensils, and Supplies (31,687 awards), Medical and Surgical Instruments, Equipment, and Supplies (6,392 awards), and Drugs and Biologicals (2,903 awards).

Activity has declined year over year — 3,664 awards in 2022 declining to 975 in 2026 year-to-date — suggesting portfolio maturation or shift away from high-volume DLA ordering. Seventy-six awards with ultimate completion dates in the next twenty-four months carry $72 million in combined potential value, representing recompete exposure for Abbott and recompete opportunity for competitors positioned on those same vehicles. Abbott Laboratories, the parent entity, holds no named federal prime awards or vehicle positions; the Point of Care Division operates independently within the federal market.